Knight Therapeutics Inc. (TSE:GUD - Get Free Report) shares were down 2.5% during trading on Thursday . The stock traded as low as C$5.15 and last traded at C$5.15. Approximately 107,624 shares traded hands during trading, an increase of 36% from the average daily volume of 78,912 shares. The stock had previously closed at C$5.28.
Analyst Upgrades and Downgrades
Separately, Raymond James raised shares of Knight Therapeutics to a "moderate buy" rating in a research note on Friday, November 15th.
Read Our Latest Report on GUD
Knight Therapeutics Price Performance
The firm has a market capitalization of C$526.29 million, a PE ratio of -26.00, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a quick ratio of 1.79, a current ratio of 3.41 and a debt-to-equity ratio of 7.62. The stock has a 50-day moving average price of C$5.46 and a 200 day moving average price of C$5.65.
Insider Activity
In related news, Director Samira Sakhia acquired 20,000 shares of the stock in a transaction on Monday, November 11th. The shares were bought at an average price of C$5.15 per share, with a total value of C$103,000.00. Also, insider Sime Armoyan sold 300,000 shares of the firm's stock in a transaction on Monday, September 16th. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00. Company insiders own 45.62% of the company's stock.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Further Reading
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
